SPR Molecular Binding Lab

1. Kretschmann Optical SPR Configuration

Surface Plasmon Resonance relies on total internal reflection (TIR) of p-polarized light at a glass-gold interface. At a precise incident angle $\theta_{\text{SPR}}$, photons couple with free electron collective oscillations (plasmons) in the gold thin film:

An evanescent electromagnetic field extends $\sim 200\text{ nm}$ into the liquid flow channel. As biomolecules bind to immobilized surface receptors, the local refractive index increases, shifting the minimum reflectance angle ($\Delta\theta_{\text{SPR}}$) in direct proportion to bound mass ($1\text{ RU} \approx 1\text{ pg/mm}^2$).

2. 1:1 Langmuir Binding Kinetics

The fundamental reversible bimolecular binding interaction between analyte ($A$) in flow and immobilized ligand ($B$) is governed by:

• Association: Driven by analyte concentration $C$ and forward association rate constant $k_{\text{on}}$ ($\text{M}^{-1}\text{s}^{-1}$): $R(t) = R_{\text{eq}} [1 - e^{-(k_{\text{on}} C + k_{\text{off}}) t}]$.
• Dissociation: Following buffer injection, complex dissociates at off-rate $k_{\text{off}}$ ($\text{s}^{-1}$): $R(t) = R_0 e^{-k_{\text{off}} t}$.
• Complex Half-Life: $t_{1/2} = \ln(2) / k_{\text{off}}$ (critical metric for therapeutic antibody residency time).

3. Mass Transport & Sensor Surface Chemistries

Accurate kinetics require eliminating artifactual mass transport limitations (MTL):

• Two-Compartment Transport: If diffusion from the bulk laminar stream to the dextran matrix is slower than binding, the apparent association rate is artificially throttled. High microfluidic flow rates ($>30\ \mu\text{L/min}$) and low immobilization densities ($R_{\text{max}} < 100\text{ RU}$) eliminate MTL.
• CM5 Dextran: High-capacity flexible hydrogel matrix for standard EDC/NHS primary amine coupling.
• NTA & Protein A: Site-directed, oriented capture of His-tagged enzymes and Fc-tagged antibodies avoiding active site occlusion.

4. Biopharma Screening Economics

Label-free real-time kinetics is universally required by regulatory authorities (FDA/EMA) for IND filings and antibody characterization:

• Affinity Ranking: Differentiating therapeutic candidates with identical nanomolar $K_D$ values but vastly different off-rates ($k_{\text{off}}$).
• Biosimilar Comparability: Demonstrating analytical biosimilarity of biosimilars against reference drugs (e.g., Herceptin, Humira).
• Laboratory ROI: High sample automation (96- and 384-well plates) enables rapid throughput, generating over \$280k in annual revenue and achieving capital payback within 1.1 years.